Mariam Nawas, MD

Mariam Nawas, MD

Hematology and Oncology

Accepts New Patients

Download Contact Information

Request Appointment

Please call the office to schedule an appointment with this provider.

Call the Office

Back to Top

Locations

A

Hinsdale

UChicago Medicine AdventHealth Hematology & Oncology Hinsdale
1 Salt Creek Lane
 Hinsdale, IL  60521
630-286-5500
Back to Top

UChicago Faculty Physicians hold faculty positions with the University of Chicago and provide care for patients on the academic health system's main campus in Hyde Park and in care centers throughout the Chicago region. UChicago Faculty Physicians who provide services at UChicago Medicine AdventHealth Bolingbrook, Hinsdale, La Grange and GlenOaks hospitals are independent providers with privileges at those hospitals. Except as otherwise denoted, independent providers are not employees or agents of UChicago Medicine AdventHealth Bolingbrook, Hinsdale, La Grange and GlenOaks hospitals.

Expertise

Biography

Dr. Nawas, MD is board-certified in Hematology and Oncology. Her specialties include:

  • Bone Marrow transplantation
  • Leukemias
  • Clonal cytopenias
  • CAR T-cell therapy
  • Cellular Therapy
    • Care Philosophy

    Dr. Nawas is an expert in treating patients suffering from leukemias. She is passionate about using research to improve care and quality of life for all patients.

    Areas Served
    Hinsdale, IL
    Languages Spoken
    Arabic, English
    Education
    • University of Missouri, Kansas City
    Residencies
    • Internal Medicine at University of California, San Francisco
    Fellowships
    • Hematology & Oncology at Memorial Sloan Kettering Cancer Center
    Medical Organization Memberships and Committees
    • American Society of Hematology
    • American Society of Transplantation and Cellular Therapy
    Publications
    • Yates SJ, Cursio JF, Artz AS, Kordas K, Bishop MR, Derman BA, Kosuri S, Riedell PA, Kline J, Jakubowiak A, Mortel M, Johnson S, Nawas MT, Yates SJ, Cursio JF, Artz A, Kordas K, Bishop MR, Derman BA, Kosuri S, Riedell PA, Kline J, Jakubowiak A, Mortel M, Johnson S, Nawas MT. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 Jul 23; 8(14):3785-3797. PMID: 38810262; PMCID: PMC11298834.
    • Kaur A, Rojek AE, Symes E, Nawas MT, Patel AA, Patel JL, Sojitra P, Aqil B, Sukhanova M, McNerney ME, Wu LP, Akmatbekov A, Segal J, Tjota MY, Gurbuxani S, Cheng JX, Yeon SY, Ravisankar HV, Fitzpatrick C, Lager A, Drazer MW, Saygin C, Wanjari P, Katsonis P, Lichtarge O, Churpek JE, Ghosh SB, Patel AB, Menon MP, Arber DA, Wang P, Venkataraman G. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 Jun 18; 14(1):99. PMID: 38890297; PMCID: PMC11189545.
    • Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Apr 11. PMID: 38618681.

      More items loaded

    • He G, Belmont E, Karrison T, Stock W, LaBelle JL, Kosuri S, Larson RA, Kline JP, Riedell PA, Nawas M, Bishop MR, Liu H. FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49. PMID: 38911560; PMCID: PMC11193555.
    • Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AA. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6): 864-867-PMID: 38441062.
    • Nawas MT, Kosuri S. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML. Blood Adv. 2024 02 13; 8(3): 553-561-PMID: 38096805; PMCID: PMC10835231.
    • Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin C. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171. PMID: 38039510; PMCID: PMC10787242.
    • Rojek AE, Kline JP, Feinberg N, Appelbaum DE, Pu Y, Derman BA, Jakubowiak A, Kosuri S, Liu H, Nawas MT, Smith SM, Bishop MR, Riedell PA. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93. PMID: 37827881.
    • Nawas MT, Im A, Shaffer B. Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy. Blood Adv. 2023 08 22; 7(16):4475-4478. PMID: 37315168; PMCID: PMC10440450.
    • Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239. PMID: 36655425; PMCID: PMC10388285.
    • Nawas MT, Scordo M. Linking Body Composition and Nutritional Status with CAR T-cell Efficacy. Cancer Immunol Res. 2023 06 02; 11(6):704. PMID: 37264818.
    • Nawas MT, Scordo M. Linking Body Composition and Nutritional Status with CAR T-cell Efficacy. Cancer Immunol Res. 2023 May 05; OF1. PMID: 37145089.
    • Nawas MT, Sanchez-Escamilla M, Devlin SM, Maloy MA, Ruiz JD, Sauter CS, Giralt SA, Perales MA, Scordo M. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2022 11 22; 6(22):5898-5907. PMID: 35977079; PMCID: PMC9661383.
    • Cooperrider JH, Shukla N, Nawas MT, Patel AA. The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncol Pract. 2023 02; 19(2):74-85. PMID: 36223559; PMCID: PMC10476749.
    • Nawas MT, Lee JO, Flynn J, Maloy M, Jakubowski AA, Papadopoulos EB, Cho C, Ponce DM, Sauter CS, Perales MA, Devlin S, Giralt SA, Castro-Malaspina HR, Tamari R. CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. Bone Marrow Transplant. 2022 07; 57(7):1101-1107. PMID: 35484207; PMCID: PMC10015419.
    • Nawas MT, Shah GL, Feldman DR, Ruiz JD, Robilotti EV, Aslam AA, Dundas M, Kamboj M, Barker JN, Cho C, Chung DJ, Dahi PB, Giralt SA, Gyurkocza B, Lahoud OB, Landau HJ, Lin RJ, Mailankody S, Palomba ML, Papadopoulos EB, Politikos I, Ponce DM, Sauter CS, Shaffer BC, Scordo M, van den Brink MRM, Perales MA, Tamari R. Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. Transplant Cell Ther. 2021 05; 27(5):438.e1-438.e6. PMID: 33728417; PMCID: PMC7952254.
    • Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4): 531-539-PMID: 33059999.
    • Nawas MT, Levine RL, Perales MA, Giralt SA, VanDenBrink MR, Arcila ME, Zehir A, Papaemmanuil E, Klussmeier A, Bolton KL, Tamari R, Schetelig J, Damm F, Schmidt AH, Maiwald S. The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Rev. 2021 03; 46:100744. PMID: 32896435; PMCID: PMC8278242.
    • Nawas MT, Landau HJ, Sauter CS, Featherstone CA, Kenny SA, Rodriguez ES, Johnson LG, Giralt SA, Scordo M. Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):e135-e137. PMID: 32070723; PMCID: PMC7594444.
    • Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):1218-1224. PMID: 30708189.
    • Nawas MT, Walker EJ, Richie MB, White AA, Hsu G. A Protean Protein. J Hosp Med. 2019 02 01; 14(2):117-122. PMID: 30534640.
    • Nawas MT, Daruwalla VJ, Spirer D, Micco AG, Nemeth AJ. Complicated necrotizing otitis externa. Am J Otolaryngol. 2013 Nov-Dec; 34(6):706-9. PMID: 23927998.
    Ages Accepted
    • Adults
    • Geriatrics
    Back to Top

    Frequently Asked Questions

    What locations does Mariam Nawas, MD practice at?
    Mariam Nawas, MD practices at Hinsdale at 1 Salt Creek Lane, Hinsdale, IL, 60521. Learn more about Mariam Nawas, MD at AdventHealth.
    What is Mariam Nawas, MD's specialty?
    Mariam Nawas, MD specializes in Hematology and Oncology. Learn more about Mariam Nawas, MD at AdventHealth.
    What conditions does Mariam Nawas, MD treat?
    Mariam Nawas, MD treats the following conditions: Biopsy, Cancer, Coagulation, Immunotherapy, Leukemia, Medical Oncology, Oncology, Radiotherapy and Stem Cell Transplantation. Learn more about Mariam Nawas, MD at AdventHealth.
    What health services does Mariam Nawas, MD provide?
    Mariam Nawas, MD provides Cancer Care services. Learn more about Mariam Nawas, MD at AdventHealth.